Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ORTHO-EST vs EVAMIST
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Estradiol is a steroid hormone that binds to and activates estrogen receptors (ERα and ERβ), leading to regulation of gene transcription and modulation of various physiological processes including reproductive function, bone metabolism, and cardiovascular health.
Evamist (estradiol transdermal spray) is a form of estrogen hormone replacement therapy. Estrogens diffuse into target cells and bind to estrogen receptors, which then translocate to the nucleus and regulate gene transcription, leading to estrogenic effects.
Treatment of moderate-to-severe vasomotor symptoms due to menopause,Prevention of postmenopausal osteoporosis,Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure,Atrophic vaginitis,Kraurosis vulvae
Treatment of moderate to severe vasomotor symptoms due to menopause,Off-label: Prevention of postmenopausal osteoporosis (not FDA-approved for this indication)
1.25 mg orally once daily for 21 days, followed by 7 days off; or 0.625 mg orally once daily continuously.
1.53 mg per actuation (as estradiol hemihydrate); 1 spray to the inner forearm once daily.
12-18 hours (terminal elimination half-life); clinical context: dosed once daily, steady-state achieved in 5-7 days.
Terminal elimination half-life is 4 hours; clinical context: dosing every 6-8 hours maintains therapeutic levels
Primarily hepatic via CYP3A4; undergoes enterohepatic recirculation; metabolites include estrone, estriol, and conjugates.
Estradiol is primarily metabolized in the liver via CYP3A4 and other cytochrome P450 enzymes. It is also metabolized in the gastrointestinal tract and skin. Major metabolites include estrone and estriol, which are conjugated (sulfates and glucuronides) and excreted in urine.
Renal elimination (90-95%) as glucuronide and sulfate conjugates; fecal (5-10%) via biliary excretion.
Renal (90%) as metabolites; fecal (<5%); biliary (<1%)
50-80% bound to albumin and sex hormone-binding globulin (SHBG); binding to SHBG is approx. 30-50%.
80% bound to albumin and alpha-1-acid glycoprotein
1-2 L/kg; clinical meaning: extensive distribution into tissues, including fat and reproductive organs.
3-5 L/kg; indicates extensive tissue distribution
Oral: 40-60% due to first-pass metabolism; transdermal: approximately 10-20% systemic availability (not primary route).
Intranasal: 70%; oral: not applicable (first-pass metabolism)
No dose adjustment required for mild to moderate renal impairment. Severe renal impairment (GFR <30 m L/min): use with caution due to potential accumulation of conjugated estrogens.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use with caution.
Child-Pugh Class A: no adjustment. Child-Pugh Class B or C: contraindicated due to impaired estrogen metabolism.
Contraindicated in Child-Pugh Class B and C (moderate to severe hepatic impairment). No data for mild impairment; use with caution.
Not indicated for use in pediatric patients.
Not indicated for use in pediatric patients. Safety and efficacy not established.
Initiate at lowest effective dose (0.625 mg orally once daily) and titrate cautiously due to increased risk of thromboembolic events and endometrial cancer.
No specific dose adjustment recommended; however, initiate at lowest effective dose due to increased risk of adverse effects (e.g., thromboembolism, malignancy) in elderly.
Estrogens increase the risk of endometrial cancer in postmenopausal women with an intact uterus. They should not be used during pregnancy. There is an increased risk of cardiovascular events (e.g., stroke, myocardial infarction) and breast cancer with estrogen-alone therapy.
Estrogen therapy increases the risk of endometrial cancer in women with an intact uterus. Use of unopposed estrogens is associated with an increased risk of endometrial hyperplasia and carcinoma. Additionally, estrogens should not be used to prevent cardiovascular disease or dementia. The Women's Health Initiative (WHI) study reported increased risks of stroke, deep vein thrombosis, pulmonary embolism, and breast cancer with estrogen-alone therapy.
Cardiovascular disorders (thrombophlebitis, thromboembolism), malignancy (breast, endometrial), gallbladder disease, hypercalcemia, fluid retention, hepatic impairment, hypothyroidism, and hereditary angioedema.
Risk of endometrial cancer: Use progestin in women with intact uterus.,Cardiovascular disorders: Increased risk of stroke, DVT, pulmonary embolism, especially in smokers and older women.,Breast cancer: Increased risk with long-term use.,Dementia: Increased risk in women ≥65 years old.,Gallbladder disease.,Hypercalcemia in patients with breast cancer and bone metastases.,Retinal vascular thrombosis: Discontinue if sudden vision loss occurs.,Fluid retention: Use with caution in patients with conditions exacerbated by edema.,Hypothyroidism: May need increased thyroid replacement dose.,Hepatic impairment: Contraindicated in severe liver disease.
Known or suspected pregnancy, undiagnosed abnormal genital bleeding, known or suspected breast cancer (except in select cases), known or suspected estrogen-dependent neoplasia, active or history of venous thromboembolism, active or history of arterial thromboembolism, hypersensitivity to estrogens, hepatic impairment or disease, protein C, protein S, or antithrombin deficiency.
Undiagnosed abnormal genital bleeding,Known, suspected, or history of breast cancer,Known or suspected estrogen-sensitive neoplasia,Active or history of deep vein thrombosis or pulmonary embolism,Active or history of arterial thromboembolic disease (e.g., stroke, MI),Known thrombophilic disorders (e.g., Protein C, S, or antithrombin deficiency),Hepatic impairment or disease,Pregnancy,Hypersensitivity to estradiol or any ingredient
Grapefruit juice may increase systemic exposure to esterified estrogens; avoid concurrent consumption. No other significant food interactions are documented.
Grapefruit and grapefruit juice may increase estradiol levels; avoid excessive consumption. No other significant food interactions reported.
ORTHO-EST (estradiol) is a pregnancy category X drug. Use is contraindicated during pregnancy. First trimester exposure is associated with a risk of congenital anomalies (e.g., cardiovascular, limb defects, VACTERL association) based on epidemiological data. Second and third trimester exposure may cause fetal harm including urogenital tract abnormalities and potential carcinogenic effects. Estrogens are not recommended for use in pregnancy.
Evamist (estradiol transdermal spray) is contraindicated in pregnancy. First trimester exposure is associated with congenital anomalies including cardiovascular and limb defects. Second and third trimester exposure increases risk of urogenital abnormalities and potential long-term reproductive tract effects in offspring. Use is not recommended at any gestational stage.
Estradiol is excreted in human breast milk at low concentrations. The M/P ratio is approximately 0.2–0.3. It may reduce milk production and quality. Use during breastfeeding is generally not recommended, especially in the immediate postpartum period when milk supply is being established. Alternate methods of contraception should be considered.
Estradiol is excreted in breast milk. The milk-to-plasma ratio is approximately 0.1-0.2. Studies show low concentrations in milk, but long-term effects on the infant are unknown. Evamist is not recommended during breastfeeding due to potential hormonal disruption and reduced milk production.
ORTHO-EST is contraindicated in pregnancy. No dose adjustment recommendations exist for use during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) theoretically may require dose adjustment if used, but due to teratogenicity, it should not be used. Postpartum, if estrogen therapy is indicated, consider lower doses due to altered metabolism and risk of thromboembolism.
No dosing adjustments applicable as Evamist is contraindicated in pregnancy. In the non-pregnant state, no dosage adjustment is needed. Pharmacokinetic changes during pregnancy (increased clearance, volume of distribution) are not relevant as the drug should not be used.
ORTHO-EST (esterified estrogens) is indicated for moderate to severe vasomotor symptoms due to menopause and for prevention of postmenopausal osteoporosis. It carries a boxed warning for endometrial cancer in women with an intact uterus; co-administration with a progestin is required unless the patient has had a hysterectomy. Risk of venous thromboembolism is increased; avoid in patients with active VTE or history of VTE. Estrogen use may increase risk of breast cancer, especially with prolonged use (>5 years). Do not use in women with undiagnosed abnormal genital bleeding. Monitor for signs of hypercalcemia in patients with metastatic breast cancer or hypoparathyroidism.
Apply EVAMIST to clean, dry, intact skin of the axilla or inner thigh. Avoid application to irritated or broken skin. Rotate application sites to minimize local skin reactions. Do not apply to the breast or vaginal area. For optimal absorption, wait at least 1 hour after application before showering or swimming. Monitor serum estradiol levels if inadequate symptom relief or adverse effects occur.
Take ORTHO-EST exactly as prescribed; do not increase dose or frequency without consulting your doctor.,If you have a uterus, you must also take a progestin to protect against endometrial cancer risk.,Report any unusual vaginal bleeding, breast lumps, or changes in discharge promptly.,Avoid smoking while taking estrogen therapy; smoking increases risk of serious cardiovascular events.,Notify your healthcare provider if you develop symptoms of blood clot: sudden leg pain/swelling, chest pain, shortness of breath, or vision changes.,This medication does not prevent pregnancy; use appropriate contraception unless advised otherwise.,Store at room temperature away from moisture and heat.
Apply the gel to clean, dry skin on your armpit or inner thigh.,Rotate application sites daily to avoid skin irritation.,Avoid applying to the breast or vaginal area.,Do not wash the application area for at least 1 hour after applying.,Keep away from children and pets; wash hands thoroughly after application.,Do not use if you are pregnant, breastfeeding, or have a history of certain cancers.,Report any unusual vaginal bleeding, breast lumps, or signs of blood clots immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ORTHO-EST vs EVAMIST, answered by our medical review team.
ORTHO-EST is a Estrogen Replacement that works by Estradiol is a steroid hormone that binds to and activates estrogen receptors (ERα and ERβ), leading to regulation of gene transcription and modulation of various physiological processes including reproductive function, bone metabolism, and cardiovascular health.. EVAMIST is a Estrogen Replacement that works by Evamist (estradiol transdermal spray) is a form of estrogen hormone replacement therapy. Estrogens diffuse into target cells and bind to estrogen receptors, which then translocate to the nucleus and regulate gene transcription, leading to estrogenic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ORTHO-EST and EVAMIST depend on the specific clinical indication. These are both Estrogen Replacement agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ORTHO-EST is: 1.25 mg orally once daily for 21 days, followed by 7 days off; or 0.625 mg orally once daily continuously.. The standard adult dose of EVAMIST is: 1.53 mg per actuation (as estradiol hemihydrate); 1 spray to the inner forearm once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ORTHO-EST and EVAMIST in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ORTHO-EST is classified as Category C. ORTHO-EST (estradiol) is a pregnancy category X drug. Use is contraindicated during pregnancy. First trimester exposure is associated with a risk of congenital anomalies (e.g., car. EVAMIST is classified as Category C. Evamist (estradiol transdermal spray) is contraindicated in pregnancy. First trimester exposure is associated with congenital anomalies including cardiovascular and limb defects. S. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.